You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CPD

Ocular Complications in Hematological Malignancies: Recognition, Mitigation, and Management

  • Authors: Elisabeth Messmer, MD; Marc Labetoulle, MD, PhD; Sagar Lonial, MD, FACP; and Mohamed Mohty, MD, PhD
  • CPD Released: 4/21/2021
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
  • Valid for credit through: 4/21/2022
Start Activity


Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US hematology and oncology specialists and ophthalmologists.

The goal of this activity is to educate physicians and ophthalmologists on the potential eye toxicities associated with anticancer drugs used to treat hematological malignancies, and their practical mitigation and management.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Potential ocular complications associated with the treatment of patients with hematological malignancies
    • Mitigation strategies for drug-associated ocular toxicities
  • Have greater competence related to
    • Managing ocular adverse events in patients with multiple myeloma


Disclosures

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.


Faculty

  • Elisabeth Messmer, MD

    Professor
    Department of Ophthalmology
    University of Munich
    Munich, Germany

    Disclosures

    Disclosure: Elisabeth Messmer, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Alcon; DMG; Dompé; Kala; Novartis; Pharm-Allergan; Santen; Shire; SIFI; Sun; Théa Pharma; TRB Chemedica; VISUfarma
    Served as a speaker or a member of a speakers bureau for: Alcon; Dompé; Novartis; Pharm-Allergan; Santen; Théa Pharma; TRB Chemedica AG; URSApharm; VISUfarma
    Received grants for clinical research from: Chiesi

  • Marc Labetoulle, MD, PhD

    Professor and Chair
    Ophthalmology Department
    Bicêtre Hospital
    Paris Saclay University
    Paris, France

    Disclosures

    Disclosure: Marc Labetoulle, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Alcon; Allergan; Bausch & Lomb; DMG; Dompé; GlaxoSmithKline; Horus; Merck Sharp & Dohme, Corp.; Novartis; Quantel; Santen; Shire; TopiVert; Théa Pharma
    Served as a speaker or a member of a speakers bureau for: Alcon; Allergan; Bausch & Lomb; DMG; Dombé; GlaxoSmithKline; Horus; Merck Sharp & Dohme, Corp.; Novartis; Quantel; Santen; Shire; TopiVert; Théa Pharma
    Received grants for clinical research from: Théa Pharma

  • Sagar Lonial, MD, FACP

    Professor and Chair
    Department of Hematology and Medical Oncology
    Emory University
    Atlanta, Georgia, United States
    The opinions expressed are those of Dr Lonial and do not necessarily reflect the views of Emory University or Emory Healthcare. Dr Lonial's participation in this activity does not constitute or imply endorsement by Emory University or Emory Healthcare.

    Disclosures

    Disclosure: Sagar Lonial, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AbbVie; Amgen; Bristol Myers Squibb Company; Celgene; GlaxoSmithKline; Janssen; Novartis; Takeda
    Received grants for clinical research from: Bristol Myers Squibb Company; Takeda
    Owns stock, stock options, or bonds from: Board of directors TG Therapeutics

  • Mohamad Mohty, MD, PhD

    Professor
    Hospital Saint-Antoine and
    Sorbonne University
    Paris, France

    Disclosures

    Disclosure: Mohamad Mohty, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Amgen; Janssen; Jazz; Sanofi; Takeda
    Served as a speaker or a member of a speakers bureau for: Amgen; Astellas; Celgene; GlaxoSmithKline; Janssen; Jazz; Novartis; Pfizer; Sanofi; Takeda
    Received grants for clinical research from: Roche; Sanofi

Editors

  • Sanneke Koekkoek

    Medical Education Director, WebMD Global, LLC 

    Disclosures

    Disclosure: Sanneke Koekkoek has disclosed no relevant financial relationships.

  • Jason L. Quinones, PhD

    Scientific Content Manager, Medscape, LLC 

    Disclosures

    Disclosure: Jason L. Quinones, PhD, has disclosed no relevant financial relationships.

Content Reviewer

  • Hazel Dennison, DNP, RN, FNP-BC, CHCP, CPHQ, CNE

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Disclosure: Hazel Dennison, DNP, RN, FNP-BC, CHCP, CPHQ, CNE, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements

    For Physicians

  • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

    Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

  1. Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
  2. Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CPD

Ocular Complications in Hematological Malignancies: Recognition, Mitigation, and Management

Authors: Elisabeth Messmer, MD; Marc Labetoulle, MD, PhD; Sagar Lonial, MD, FACP; and Mohamed Mohty, MD, PhDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED FOR CREDIT

CPD Released: 4/21/2021

Valid for credit through: 4/21/2022

processing....

Educational Impact Challenge

The goal of this activity is to educate physicians and ophthalmologists on the potential eye toxicities associated with anticancer drugs used to treat hematological malignancies, and their practical mitigation and management.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print